Arecor to retain Inhibrx royalties in wake of Sanofi acquisition

The com­pa­ny that de­vel­oped the tech­nol­o­gy be­hind Sanofi’s pur­chase of In­hi­brx said that roy­al­ty oblig­a­tions won’t change with the ac­qui­si­tion.

Arecor, a Cam­bridge, UK start­up, will re­tain roy­al­ties to IN­BRX-101, Sanofi’s pri­ma­ry ac­qui­si­tion tar­get, fol­low­ing a li­cens­ing agree­ment be­tween Arecor and In­hi­brx from 2020, ac­cord­ing to a press re­lease. The an­nounce­ment comes af­ter Arecor re­ceived a mile­stone pay­ment from In­hi­brx last No­vem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.